metastatic/advanced RCC (mRCC) - 1st line (L1) | |
mRCC - L1 - PDL1 negative | |
atezolizumab plus bevacizumab | IMmotion-151 ... |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -